"csv
or services associated with;Substantial contribution criteria;DNSH;criteria;(""does no significant harm"");significant harm;3 a &lt;&gt; 2 fd S 2 3 a;Y;N;x 2 o S 5 ry &lt; ia sq 56 es a BS 2g Ss =5 ag;Y;N in %;2 3 3 s cy 2 o&gt; gz £2 6&amp;8 E
;Taxonomy-aligned economic activities;—;;;as 5S fe cs £8 £ é8 On N/EL;Y;N;;;3 q
.;disclosure covering year 2023;gs 8;e 5 2x 83;g § th sf 8g;;;zg z 5 re 5 s;;;3 = = - 2 3s s;&gt; 5 8 § of 8 3 £3;;;5 3 a &gt; 2 id 3 2 3;2 Bo 290 gc gs oS 2k gs Es;F So S 2 € &amp; 5 £ g PS § 5 2 £ 3;2 a &lt; § 5 2 o&gt; gz #2
;ECONOMIC ACTIVITIES;Oo;to €in mio;as in %;Y;N;N/EL;Y;N;5;N/EL;Y;N;Y;N;a N/EL;SR;Y;N;&amp;8
;A. TAXONOMY-ELIGIBLE ACTIVITIES;;;;;;;
;A.1. Environmentally sustainable activities (Taxonomy-aligned);;;;
;OpEx of environmentally sustainable activities (Taxonomy-aligned) (A.1.);0.0;0.0;0.0;0.0;;;;;;;;
;Of which enabling;0.0;0.0;0.0;0.0;;;;;;;;
;Of which transitional;0.0;0.0;0.0;0.0;EL;N/EL;N/EL;EL;N/EL;N/EL;N/EL;N/EL;N/EL;N/EL;N/EL;N/EL;N/EL;N/EL;N/EL;N/EL;N/EL
;A.2.Taxonomy-eligible but not environmentally sustainable activities;;;;;;;
;(not Taxonomy-aligned acti s) Manufacture of active pharma-;;;;;;;
;ceutical ingredients (API) or active substances;PPC 1.1;27.7;2.3;N/EL;N/EL;N/EL;EL;N/EL;N/EL;;;;;;;;
;Manufacture of medicinal products;PPC 1.2;561.7;45.8;N/EL;N/EL;N/EL;EL;N/EL;N/EL;;;;;;;;
;Manufacture of electrical and electronic equipment;CE 1.2;51.7;4.2;N/EL;N/EL;N/EL;N/EL;EL;N/EL;;;;;;;;
;OpEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2.);641.0;52.2;;;;;;;;
;A. OpEx of Taxonomy-eligible activities (A.1. + A.2.);641.0;52.2;0.0;;;;;;;;
;B. TAXONOMY-NON-ELIGIBLE ACTIVITIES;;;;;;;
;OpEx of Taxonomy-non-eligible activities (B.);586.3;47.8;;;;;;;;
;Total (A.+B.);1,227.3;100.0;;;;;;;;"
